Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2015-03-12 Board/Management Inform…
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 95% confidence The document is a press release dated March 12, 2015, announcing strategic business developments: the opening of an Asia branch in Hong Kong and the hiring of key personnel in Europe (Italy, Switzerland, Finland). This content relates to management strategy, expansion, and personnel changes, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It specifically details changes in senior management/business development roles and strategic operational expansion. This aligns best with the 'Board/Management Information' category, as it discusses strategic hires and executive appointments impacting business development, even though it's not strictly a board change announcement. Given the options, MANG (Board/Management Information) is the most appropriate fit for announcements concerning strategic executive hires and business leadership expansion.
2015-03-12 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 98% confidence The document is a press release dated March 12, 2015, announcing strategic business developments: the opening of a subsidiary in Hong Kong for Asian expansion and new management appointments in Europe (Italy, Switzerland, Finland). This content directly relates to changes in the company's operational structure and senior personnel, fitting the definition of Board/Management Information (MANG), which covers senior management changes and strategic organizational updates, even if it's not a formal board change announcement. It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a director's trade (DIRS).
2015-03-12 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 12, 2015, announcing the publication of positive long-term results from an international multicenter study regarding the treatment of breast fibroadenomas using the Echopulse® system. It details clinical outcomes, quotes investigators, and provides company background. This content structure—announcing study results and providing context—is characteristic of an Earnings Release (ER) or a general press release related to company performance/developments. Since it is not a formal regulatory filing like a 10-K, nor a transcript (CT), nor a specific financial report (IR, AR), and it focuses on clinical/product news rather than just financial highlights, it fits best as a general announcement. Given the options, 'Earnings Release' (ER) is often used broadly for significant operational/clinical announcements that impact investor perception, although 'Regulatory Filings' (RNS) could also apply if it were a mandatory disclosure. However, the content is a detailed announcement of study results, which often accompanies or precedes financial reporting periods. Since it is a press release announcing significant clinical data, and not a formal financial report itself, ER is the closest fit for a major operational update, though RNS is a strong secondary candidate if ER is strictly reserved for quarterly financial figures. Given the context of a major study result announcement, ER is selected as the primary classification for significant operational news releases.
2015-02-12 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is an announcement by Theraclion detailing the long-term results of a clinical study regarding their Echopulse® device for treating breast fibroadenoma. It highlights key findings (effectiveness, safety, patient satisfaction) and references a publication in the 'Journal Therapeutic Ultrasound'. This structure—a press release announcing positive clinical/research outcomes, often referencing external publications or studies—is characteristic of an Investor Presentation (IP) or a general announcement. Since it is not a formal regulatory filing (like 10-K, IR, or ER), nor a management change (MANG) or dividend notice (DIV), and it presents detailed data/results intended for investors/stakeholders, 'Investor Presentation' (IP) is the most fitting category, although it functions as a press release. Given the options, it is a communication focused on presenting specific data and results to the investment community about a product's success, which aligns closely with the intent of an IP, rather than a general Regulatory Filing (RNS). It is not short enough to be a simple RPA.
2015-02-12 English
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document explicitly announces the 'chiffre d'affaires annuel 2014' (annual revenue for 2014) for Theraclion, providing detailed financial figures for the full year ending December 31, 2014. This content structure—a press release detailing yearly financial performance highlights, including revenue tables and management commentary on the fiscal year—is characteristic of an Earnings Release (ER). Although it covers the full year, it is presented as an initial announcement of results rather than the comprehensive, audited 10-K filing. The document is short and formatted like a press release, not a full statutory report. The final line mentions the 'Prochain communiqué de presse financier : résultats de l'exercice 2014, le 19 mars 2015', which confirms this document is the preliminary release of the annual results. FY 2014
2015-01-29 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 98% confidence The document is titled "Theraclion Reports 2014 Revenues of 800 K€" and explicitly reports annual sales revenues for the fiscal year 2014, comparing them to FY13. It contains key financial figures (Total Sales Revenues, Sales of equipment, Sales of consumables) and discusses business milestones related to those revenues. This content structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, often released before the full Annual Report (10-K) or the detailed Management Discussion and Analysis (MDA). The document also mentions the 'Next financial press release: annual results 2014, March 19th 2015', confirming this is an early release of results, not the comprehensive annual filing itself. Therefore, 'ER' is the most appropriate classification. FY 2014
2015-01-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.